ResMed closes acquisition of medical device firm Inova Labs

US manufacturer ResMed has completed the acquisition of Texas-based medical device firm Inova Labs, which is involved in developing oxygen therapy products.

Free Report

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.

By GlobalData

By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Although initially announced last month January, the deal’s terms have not been disclosed.

The deal allows ResMed to expand its care offerings and solutions to treat people with chronic obstructive pulmonary disease (COPD).

Currently, ResMed’s respiratory care offerings include products such as the AirCurve 10 series of cloud-connected non-invasive ventilators, the Stellar series of non-invasive ventilators, and the Astral series.

"This acquisition is an important step to reach our goal of improving 20 million lives by 2020."

Astral is a lightweight non-invasive life-support platform with internal and external batteries that provide up to 24 hours of freedom for patients.

ResMed CEO Mick Farrell said: "We are excited to complete this acquisition, which expands our offerings and solutions to address a global COPD epidemic impacting tens of millions of people.

"This acquisition is an important step to reach our goal of improving 20 million lives by 2020."

The acquisition adds ResMed with both portable oxygen concentrators and necessary stationary options for the home.

Inova Labs produces LifeChoice Activox, which is a lightweight and portable oxygen concentrator that provides enhanced battery life for greater freedom and mobility.

The company’s portfolio also includes Activox DUO2, which is claimed to be the industry’s first fully integrated stationary and portable oxygen concentrator system.

Last October, ResMed acquired non-invasive ventilation and sleep-disordered breathing medical devices and accessories provider, Curative Medical.

Established in 2008, Curative designs and produces medical devices for sleep-disordered breathing and COPD.

With operations in more than 100 countries, ResMed is focused on developing devices for the diagnosis, treatment and management of sleep-disordered breathing, COPD and other chronic conditions.